We are a group of experienced researchers from GREECE. We have identified an interaction between SARS-CoV-2 SPIKE Glycoprotein and the nicotinic cholinergic pathway. This interaction is between the SPIKE Glycoprotein and the main component of this pathway, the neuronal type nicotinic acetylcholine receptors (nAChRs). This interaction is happening through a well characterized epitope, in the beginning of the Receptor Binding Domain, mainly composed by the aminoacids aa375-390. Antibodies against this epitope (like the well known anti SARS antibody CR3022) can work protectively. We are working to characterize this interaction, human recombinant antibodies are produced and the diagnostic/prognostic importance of this finding is further studied.
The number of smokers showing severe COVID-19 that requires hospitalization is by far lower than expected For the very few smokers who end up in the hospital with COVID-19, the odds of having an adverse outcome is increased compared to non-smokers. Potential benefits of Nicotine for COVID-19 disease
Cardiology – Nicotine
Immunology – Acetylcholine Receptors
Biochemistry – Bioinformatics
Neurology - Neuroimmunology